EQUITy in Black Adult Health (EQUITA) - a Randomised Feasibility Trial of a Co-produced and Faith-placed Intervention to Increase Uptake of Breast, Cervical, Bowel, and AAA Screening in the North East of England, Leeds and Scotland

The goal of this randomised feasibility trial is to examine feasibility and acceptability of a co-produced and faith-placed intervention to increase uptake of breast, cervical, bowel, and abdominal aortic aneurysm (AAA) screening among Black communities in the North East of England, Leeds and Scotland, United Kingdom (UK).
Participants will be invited to attend a two-hour workshop at each of the three study sites and will be randomly assigned to either the intervention group or the control group.
This 24-month feasibility study will inform the development of a full-scale randomised-controlled trial co-produced for Black people that uses culturally appropriate messages that support screening for early diagnosis in this underserved group.

开始日期2025-09-01

申办/合作机构

University of Sunderland

[+1]

ISRCTN65120935

/ RecruitingN/AIIT

Safeguarding adults for empowerment (SAFE): a qualitative study to develop best practice for involving older people in safeguarding processes

开始日期2024-10-08

申办/合作机构

University of Sunderland

NCT06254963

/ CompletedN/AIIT

The Effect of 6 Weeks Supplemental Jump Training on Sand Versus Hard Surfaces on Landing Knee Valgus and Jump Performance in Adolescent Female Football Players

The aim of this study is to investigate the effect of a supplemental jump training program (added to a warm up) conducted on either sand or hard surfaces on the landing and jumping ability of young female football players. The jump training program (intervention) will be carried out twice weekly for a period of 6 weeks. Participants will be randomised (computer package will decide) into one of 2 groups (either sand training or land training). The landing ability and jumping performance of all participants will be measured both before and after the 6 week jump training intervention. It is hypothesised that supplemental training on both sand and hard surfaces will improve landing ability and jumping performance. It is also hypothesised that sand will be equally as effective as a hard surface for improving jump landing ability but may be less effective than a hard surface for improving jumping performance.

开始日期2024-02-14

申办/合作机构

University of Teesside

[+1]

100 项与 University of Sunderland 相关的临床结果

登录后查看更多信息

0 项与 University of Sunderland 相关的专利（医药）

登录后查看更多信息

1,244

项与 University of Sunderland 相关的文献（医药）

2026-01-01·PROTEIN EXPRESSION AND PURIFICATION

Validation of cold shock-based technique for purification of recombinant C. elegans Phosphodiesterase 3 protein expressed in E. coli

Article

作者: Samidurai, Arun ; Carter, Noel ; Khan, Faiyaz Ahmad ; Manganiello, Vincent C ; Rhee, Dong Keun ; Sabouri, Babak ; Naik, Swapna G ; Hockman, Steven

Phosphodiesterase 3 enzymes (PDE3) play important roles in the regulation of adipocyte lipolysis and cardiac contractility by hydrolyzing cAMP and cGMP. This study reports the cloning, expression, and purification of recombinant Caenorhabditis elegans phosphodiesterase 3 (CEPDE3) isoforms, using a cold shock-based technique. The two closely related isoforms of the CEPDE3 gene (isoform F and isoform A) were cloned into the pGEX-6P-1 vector and expressed in E. coli as fusion proteins with a glutathione-S transferase (GST) tag at their amino terminus and purified by affinity chromatography using a glutathione Sepharose column. To optimize expression and recovery of soluble CEPDE3 protein from E. coli, we applied a "cold shock" technique at 4 °C following IPTG induction. Our findings suggest improved protein expression using an N-terminal GST tag instead of a C-terminal 6-histidine (6His) tag. Exposure of GST-tagged CEPDE3 to cold shock improved the protein solubility of CEPDE3 isoforms recovered by affinity chromatography. Studying CEPDE3 expression in C. elegans may enable us to understand the structure-function relationship and help crystallize the proteins to identify its catalytic pocket, contributing to the design of more effective small modulators of PDE3 catalytic activity.

2025-12-01·JOURNAL OF PUBLIC HEALTH

A brief intervention for smoking cessation in the ambulance setting—an exploratory mixed methods study to reach health equity

Article

作者: Burrow, Emma ; Charlton, Karl ; Jackson, Michelle ; Rees, Jon

Abstract:

Background:

The role of a brief intervention (BI) for smoking cessation with patients using National Health Service (NHS) ambulance services is underexplored but may reach tobacco smokers currently not engaging with NHS stop smoking services (SSS).

Methods:

A BI comprising smoking cessation education, a referral to local NHS SSS and nicotine replacement therapy (NRT) was delivered to consenting patients aged ≥18 years in a regional NHS ambulance service in England.

Results:

Of 140 patients (56% female, mean age 54.9 (14.6) years), 103 (74%) were conveyed, and 41 (29%) admitted to hospital. Outcomes included 28-day quit achieved (n = 31), current supported quit attempt (n = 6), reconsidered decision to quit/lost to follow-up after commencing NRT (n = 76), and uncontactable (n = 27). There was no association between a successful quit attempt and patient age, gender, ethnicity, or socio-economic status. Reasons behind being lost to follow-up included reconsidering the quit attempt, competing co-morbidity, and digital poverty.

Conclusion:

A BI delivered in the ambulance setting may be the only opportunity to connect tobacco smokers currently not reached by the current model, with NHS SSS. A repeated offer of support with ‘all’ smokers in this setting may help reduce disparities in health inequality.

2025-12-01·Public health in practice (Oxford, England)

Healthcare professionals’ perspectives on the implementation and purposefulness of a new alcohol recovery Navigator role in the North East of England – preliminary qualitative findings

Article

作者: Cave, Michael ; O'Donnell, Amy ; Hulse, Sarah ; Crosbie, James ; Swiers, Ryan ; Holland, Emma-Joy ; Salonen, Domna ; Christie-de Jong, Floor ; Jackson, Katherine

Objectives:

This study aimed to explore clinicians' perspectives in a single acute hospital regarding the introduction and perceived impact of an Alcohol Recovery Navigator role. The role was implemented within a hospital setting in North-East England to improve uptake of treatment in the community post-discharge and thereby help to reduce alcohol-related repeat admissions.

Study design:

A qualitative study was conducted.

Methods:

Semi-structured interviews were conducted with hospital clinicians (n = 8) recruited via purposive and snowball sampling. Interviews were transcribed verbatim, analysed using thematic analysis, with themes subsequently mapped onto Normalisation Process Theory constructs: coherence, cognitive participation, collective action, and reflexive monitoring.

Results:

Participants reported high levels of knowledge and understanding (coherence) of the Alcohol Recovery Navigator role and valued having this service as part of patients' recovery pathway. Staff appeared committed to engaging with the role (cognitive participation), which was perceived to have aided implementation and embedding of the role into patient care pathways. Participants were able to make the role work (collective action) by building relationships with hospital staff and patients to improve continuity of care. Staff appraisal (reflexive monitoring) observed increased engagement from patients with Navigators and perceived that the role contributed to patients making changes towards better health.

Conclusion:

Participants' perspectives support the continued provision of the Alcohol Recovery Navigator role. Implementation was viewed to have been successful, with Navigators imperative in bridging the gap between hospital and community care. Future research is required to assess the effectiveness of the wider programme.

项与 University of Sunderland 相关的新闻（医药）

2023-09-16

·生物制品圈

今年科学突破奖中的“帕金森小组”：他们是解码帕金森症的先驱

导读9月14日晚，万众瞩目的科学突破奖终于公布了，其中生命科学突破奖授予对抗癌症、囊性纤维化和帕金森病三个领域，共8人获奖。托马斯·加瑟（Thomas Gasser）、艾伦·西德朗斯基（Ellen Sidransky）和安德鲁·B·辛格尔顿（Andrew Singleton）3位都是帕金森领域的专家。在竞争激烈的帕金森研究领域斩获科学突破奖，那一定是该研究领域的“卷王”了。西德朗斯基对GBA1基因的研究，以及加瑟和辛格尔顿对LRRK2基因的研究，都已成为当下帕金森病遗传研究的基础性理论，这三位帕金森专家获得今年的科学突破奖可谓是实至名归。 2023年所有科学突破奖资深学者01科学突破奖授予帕金森领域3位先驱科学界的“奥斯卡奖”——科学突破奖近日揭晓，外界备受瞩目。在今年科学突破奖生命科学方向中，3位帕金森病领域的明星学者获奖。他们分别是：美国NIH的艾伦·西德朗斯基（Ellen Sidransky），德国神经退行性疾病中心的托马斯·加瑟（Thomas Gasser）和美国国立衰老研究所（NIA）的安德鲁·B·辛格尔顿（Andrew Singleton）。如下为三位学者的介绍。艾伦·西德朗斯基（Ellen Sidransky）：艾伦·西德朗斯基是美国国立卫生研究院（NIH）的儿科医生和临床遗传学家。她先后毕业于布兰迪斯大学、杜兰大学，之后又在西北大学儿童医学医院、NIH遗传学培训计划中接受培训。自2000年以来，她一直在NIH担任终身研究员和部门负责人，此外，她还是美国医师协会和儿科研究协会会员，曾获得过NIH主任奖和NHGRI指导奖。西德朗斯基致力于遗传学和神经退行性疾病的研究，工作重点是了解遗传疾病的复杂性，特别是戈谢病（GD），及其与帕金森病（PD）的联系。西德朗斯基团队曾首次确定了葡萄糖硫脂酶（GCas）作为帕金森症的风险因素。此外她还领导了NIH的一项研究计划，其中包括对患有溶酶体贮积病的患者进行评估，并发现了GBA1基因突变与帕金森病之间的联系。托马斯·加瑟（Thomas Gasser）：托马斯·加瑟是一位神经学家，先后毕业于弗赖堡大学、耶鲁大学医学院，之后在马克斯·普朗克精神病学研究所接受培训。自2002年起，一直担任赫蒂临床脑研究所神经退行性疾病部门主任；2007年以来，他还担任德国图宾根大学神经病学中心董事会的主席。2010年，加瑟博士成为图宾根大学医学院研究院长。他的主要研究领域包括帕金森病（PD）、肌张力障碍和其他运动障碍的遗传和分子基础。安德鲁·辛格尔顿（Andrew Singleton）安德鲁·辛格尔顿是一位神经再生学家，他先后毕业于桑德兰大学、泰恩河畔纽卡斯尔大学。2001年，加入美国国立卫生研究院，2006年被任命为神经遗传学实验室的主任。2020年，辛格尔顿辞去了神经遗传学实验室主任的职务，成为美国NIA新成立的阿尔茨海默病和相关痴呆症中心的代理主任。辛格尔顿研究聚焦于神经系统疾病的遗传，尤其是在帕金森病遗传病因研究。他与上文的加瑟首次确定了LRRK2基因突变是家族性和散发性帕金森病的病因。02过去的25年里，帕金森患病人数增加了一倍帕金森想必大家一定不陌生了。它是一种慢性进行性的神经系统疾病，表现为肌肉僵硬、震颤、运动缓慢和平衡困难等。1817年，英国医生詹姆斯·帕金森（James Parkinson）首次详细描述了这种疾病的症状，因此得名帕金森。帕金森的风险因素主要为年龄增长，不过一些研究表明，环境因素，包括杀虫剂，空气污染和工业溶剂等也会增加罹患帕金森的风险，男性患病的可能性比女性要高。在过去的25年里，帕金森病发病率增加了一倍，这意味着未来患这种疾病的人数可能也会迎来大幅增加。据2019年的全球统计数据，全球有850多万人患有帕金森病，这比2000年增加了81%。同时，帕金森病还导致了32.9万人死亡，与2000年相比，增幅超过了100%。这意味着帕金森病不仅变得更为常见，而且对患者的健康影响也变得更加严重，或许正因为如此，帕金森在近年来已成为大热研究领域。033位学者对帕金森研究的卓越贡献在帕金森这个领域，研究者越来越多，为何是这三位学者斩获科学突破奖？实际上，在帕金森遗传研究领域，他们算得上是“鼻祖”了。目前，与帕金森病发病风险相关的主要遗传基因大致有α-突触核蛋白、LRRK2基因、PARKIN基因、PINK1基因等，而这三位科学家则发现了其中两个基因对帕金森遗传的作用。西德朗斯基发现GBA1基因的突变与帕金森病的遗传风险有关。GBA1基因的作用是编码一种酶，这个酶在细胞内负责分解脂肪物质，如果GBA1基因突变了，就可能导致这种酶的功能出现问题，进而影响细胞内的脂质代谢异常，它被认为可能是帕金森病发生的一种机制。加瑟和辛格尔顿两人合作发现LRRK2基因中的突变与帕金森病遗传风险有关。LRRK2基因突变会导致LRRK2蛋白质的活性增加，而这种蛋白质可能对神经元产生有害影响，导致它们受损，这也被认为可能是导致帕金森病的一部分原因。基于三位学者的发现，许多科学家都是基于这两个遗传基因展开。当然，我们也期待未来能够有更多的科学家在帕金森领域有所突破。参考资料1.Thomas Gasser, MD, PhD | Parkinson's Disease.The Michael J. Fox Foundation for Parkinson's Research.2.Ellen Sidransky, M.D.Senior Investigator.NIH.3.Andrew Singleton.Wikipedia.4.帕金森病.世界卫生组织.5.BREAKTHROUGH PRIZE ANNOUNCES 2024 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS.BREAKTHROUGH PRIZE官网。6.LRRK2.Wikipedia.为促进抗体行业的交流与创新，2023年10月14-15日第六届金秋十月抗体产业发展大会如约而至。会议旨在为研究人员提供一个互动交流的平台，有助于推动抗体产业的进一步发展。会议内容时间：2023年10月14-15日地点：苏州（酒店定向通知）规模：600-800人主办单位：生物制品圈、抗体圈指导单位：康维讯生物、夏尔巴生物会议费用：免费FREE!（仅收取50元报名定金，含参会学习、茶歇、会议手册，定金概不退还），9月15日报名定金提高到100元，先到先得，报完即止，超过9月20日预登记将收取会议费！报名方式：扫描下方二维码或点击文章最底部“阅读原文”→ 填写表格 → 报名成功（报名志愿者，承担一定工作，请慎重考虑，免交定金）！组委会获得报名信息后，根据报名信息进行初筛，并进一步与报名者沟通确认，实现精准邀请。最终有机会进入大会微信群（严格审核通过）。日程安排更多嘉宾仍在邀请中。。。。。。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

基因疗法

2022-01-07

·kbio.com

BAT creates biotech company KBio to accelerate development of existing plant-based technology

KBio will leverage BAT’s existing capabilities to advance its plant-based technology and existing clinical and pre-clinical pipeline Quality Assurance and Control Certification More than 20 publication on bioanalytical methods and plant-based proteins Ph.D. in Bioanalytical Chemistry from University of Kentucky BAT today announced the launch of KBio Holdings Limited (KBio) to accelerate the research, development and production of novel treatments. KBio will leverage the existing and extensive plant-based technology capabilities of BAT and Kentucky BioProcessing Inc (KBP), the existing BAT-owned US plant biologics organisation. KBio will explore new opportunities to develop its plant-based production system, which has the potential to offer greater speed, scale-up opportunity and thermostability. The new company will focus on delivering treatments for rare and infectious diseases by realising and expanding the potential of both the plant-based technology platform, as well as its existing clinical and pre-clinical vaccines and antibody pipeline. KBio will look to form innovative R&D collaborations and financing aimed at expanding its pipeline and future portfolio, with an ambition of financial self-sufficiency. Supporting the company’s future plans, a standalone operational structure for KBio is being established. This includes building a new executive leadership team led by Patrick Doyle as the Chief Executive Officer of KBio. Mr. Doyle brings more than 20 years of experience leading innovative biotech companies. Patrick Doyle, CEO at KBio, said: “I am excited by the opportunity to build on the significant accomplishments made by BAT and KBP. I am confident in the potential of KBio’s powerful plant-based platform, capabilities and emerging early-stage pipeline. To-date, the technology has demonstrated its ability to produce novel antibody and vaccine candidates with high purity at a fraction of the time and cost of current technologies. The speed and efficiency demonstrated by the KBio platform has significant potential. This could enable us to progress to clinical studies faster than industry norms, in the hope of delivering treatment solutions more quickly.” Dr. David O’Reilly, BAT’s Director of Scientific Research, said: “Science and innovation are fundamental to BAT and delivering on our purpose of building A Better Tomorrow. We recognise the potential of our innovative plant-based technology and have established KBio to maximise that potential. We are excited to see what the future holds.” Full article PATRICK DOYLE BIO Patrick Doyle brings more than 20 years of leadership experience within pharmaceutical and biotech companies to his new role as CEO of KBio. He is a proven leader with a track record of innovation, talent development, and a deep knowledge of pharmaceutical development, M&A and pathways to successful commercialisation. He most recently served as CEO of Stelexis Therapeutics in New York, a biotech company with a proprietary platform to discover and selectively target pre-cancerous stem cells. Mr. Doyle has also been responsible for multiple financings and strategic exits of biotechs of various stages of development. During his Big Pharma tenure, he led an international group of corporate development executives executing several large alliances in Asia and Japan. Patrick is originally from the UK, and has worked in the UK, Switzerland, California and more recently in New York City. He has a BSc in Pharmacology from the University of Sunderland. ABOUT KBIO KBio aims to create a new generation of biotech solutions using its plant-based platform that has demonstrated an ability to create drug candidates at a fraction of the time and cost of current platforms. The company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response for future pandemics using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms. Formed in 2021 KBio is based in the UK and is a subsidiary of BAT For more information, please visit www.kbio.com KBio Inc is a wholly owned subsidiary of KBio Holdings Limited, a BAT Group company.

高管变更疫苗

100 项与 University of Sunderland 相关的药物交易

登录后查看更多信息

100 项与 University of Sunderland 相关的转化医学

登录后查看更多信息